Collplant Provides Update On 3D Organ Printing

April 2, 2017| Israeli biomed company CollPlant, a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, “rhCollagen”), has just provided a commercial and operational update in its annual reports.

The company has progressed to the commercial stage with the signing of Vergenix™FG and Vergenix™STR distribution and sales agreements in Europe. The company has also progressed development of 3D bioInk, the Company’s rhCollagen formulations to be used as biological ink for 3D printing of human organs and tissue. Also, the company is pursuing joint ventures with international companies to further advance bioInk in specific indications in 2017. Collplant was founded in

.